Systemic stresses induce corticotropin-releasing hormone (CRH) expression in hypothalamus. CRH is released to the pituitary gland, where it stimulates proopiomelanocortin (POMC) production acting via the CRH receptor (CRH-R). CRH and POMC peptides are also detected in sites outside of the central nervous system (CNS), such as the skin. However, it has not been elucidated whether these peptides detected in the skin are derived from CNS or are produced locally. Using immunohistochemical and in situ reverse-transcription (RT)-PCR techniques, we demonstrated coexpression of CRH and POMC mRNAs in the epidermis and pilosebaceous units of the human skin. This coexpression was confirmed by the combination of laser-capture microdissection (LCM) with RT-PCR, analyzing mRNA expressions in captured sebaceous cells. Immunoreactivities and expressions of CRH and POMC mRNAs were strong in inflammatory lesions, melanocytic nevus, seborrheic keratosis, and also in the periphery of the benign tumor. These findings suggest that CRH and POMC peptides are produced locally in the skin and are regulated by inflammatory cells as well as by autocrine mechanisms. The skin may have "a local stress response system," whose activity is mediated by CRH and POMC peptides, in an equivalent to hypothalamus-pituitary adrenal axis.
the epidermis and pilosebaceous units of the human skin. Furthermore, RT-PCR analysis revealed that the CRH, CRH-R type 1 (CRF-R1), and POMC genes are expressed in the human skin (4) . Therefore, the skin is considered to produce CRH and POMC peptides.
In this study, we aimed to elucidate the skin paracrine and autocrine circuits, which involve CRH, CRH-R, and POMC peptides, using immunohistochemistry and in situ RT-PCR. The results obtained in situ further indicate the existence of a cutaneous neuroendocrine system and confirm the hypothesis that the skin has a local stress-response system mediated by the CRH and POMC peptides equivalent to the HPA axis (5) .
MATERIALS AND METHODS

Materials
We obtained skin specimens from the scalp, face, and lower limb by biopsy or surgery of the following: 16 cases of psoriasis, 2 cases of parapsoriasis, 5 cases of melanocytic nevus, 3 cases of seborrheic keratosis, 6 cases of normal nonscalp skin, and 5 cases of normal scalp skin. We used normal human hypothalamus and rat pituitary gland samples as the positive control. For the RT-PCR assays, cDNA of the normal human thalamus, and pituitary gland (BioChain Institute, Hayward, CA) were used.
Immunohistochemistry
Tissues were fixed in 4% parahormaldehyde for 24h. Then they were embedded in paraffin and sectioned 5-m thick. We used the antigen-retrieval method with microwave oven heat for 20 min at 55 Û C for skin sections or for 10 min at 100 Û C for the hypothalamus and pituitary gland sections in citrate buffer at pH 6. Nonspecific protein binding was blocked for 5 min with a solution of 5% nonfat dry milk and 0.1% Triton X-100 added phosphate-buffered saline (PBS). For CRH-R immunostaining, Triton X-100 was not included. For CRH, CRH-R, ACTH, and.-MSH immunostaining, the sections were incubated with antibodies against CRH (Peninsula Laboratories, San Carlos, CA), CRH-R (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), ACTH (Chemicon International Inc., Temecula, CA),DQG.-MSH (Progen Biotechnik GMBH, Heiderberg, Germany) at 4 Û C overnight. We diluted the antibodies with PBS at 1:3000 (CRH), 1:1000 (CRH-R), 1:800 (.-MSH), and 1:400 (ACTH). Antigens were detected by the streptavidin-biotin-alkaline phosphate method (Vector Laboratories Inc., Burlingame, CA). For CRH immunostaining, the tyramide signal amplification (TSA) system (NEN TM Life Science Products Inc., Boston, MA) was applied according to the manufacturer protocol. Color was developed with nitroblue tetrazolium-bromochloroindolyl phosphate (NBT-BCIP; DAKO Co., Carpinteria, CA) or 3-amino-9-ethylcarbazole (ACE) (Vector Laboratories Inc.). The negative controls consisted of tissues incubated with nonimmune sera. Formalin-fixed and paraffinembedded normal human hypothalamus and rat pituitary gland samples were used as the positive control.
Reverse transcription polymerase chain reaction (RT-PCR)
We extracted total RNA from frozen tissues by using the TRIzol isolation kit following the manufacturer protocol. For the RT-PCR assays, 5g of total RNAs was transcribed by using the T-primed First-Strand kit (Ready.To.Go/Amersham Pharmacia Biotech, Inc., Piscataway, NJ). We used for examination only those samples that were proven to be free from DNA contamination by running PCR amplification with -actin primers without previous RT. The sequence of primers and conditions for PCR amplification of the 413-bp, 334-bp, and 260-bp fragments from the coding regions of the CRH, CRH-R1, and POMC genes were described in detail previously (4) . PCR was performed in a 50-l final reaction volume containing 1×PCR buffer (Promega Corporation, Madison, WI), 1.5 mM MgCl2 (Promega), 0.2 mM of a deoxynucleotide mix (Sigma Chemical, St. Louis, MO), 300 ng each of the sense and antisense primers, and 2.5 U of Taq DNA polymerase (Promega). The PCR products were separated electrophoretically on a 2% agarose gel, which was then stained with ethidium bromide and photographed under ultraviolet light. Reverse-transcribed total RNAs of the pituitary gland and brain were used as the positive controls. For the negative control, we used the following conditions: 1) RNA was not added to the reverse-transcriptase mix; 2) amplification without using reverse transcriptase; 3) PCR without using cDNA as a template. None of the negative control lanes showed any bands.
in situ RT-PCR
The same primers used for solution RT-PCR were also used for in situ RT-PCR. The biotinated probes for the detection of CRH, CRH-R, and POMC mRNAs were 5'-GCG GAG GAA GAT CTC CTC TCC C-3' for CRH cDNA, 5'-GGA CCT CAA GTT CTC CCT CGA A-3' for POMC. The in situ RT-PCR was performed following a three-step protocol as previously described (6) . Briefly, 5-P-thick sections were digested with 1 mg/ml proteinase K at 37 Û C for 10 min. After PCR, the tissue was fixed with 4% paraformaldehyde for 5 min. The slides were incubated overnight at 37 Û C in a hybridization solution containing 1 ng/ml of the specific labeled probe, as previously described (7, 8) . After hybridization, we detected signals by using streptavidin-biotin (Dako Co.). The reaction product was visualized with nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl phosphate (NBT-BCIP, Sigma). The positive controls consisted of the human hypothalamus (for CRH) and pituitary gland (for POMC). The other control experiments performed included 1) omission of reverse transcriptase or taq polymerase; 2) omission of PCR primers; and 3) pretreatment with 100 mg/ml RNase (Sigma) in PBS at 37 Û C or 2 h before RT.
Laser-capture microdissection (LCM) with RT-PCR
The tissues were fixed in Methacarn solution (9) , embedded in paraffin, cut into 8-P-thick sections, and mounted on uncoated glass slides. LCM was performed as previously described (10) . Briefly, morphologically identified sebaceous glands were laser-captured by using the PixCell LCM system (Arcuturus Engineering Inc., Mountain View, CA) onto a thermoplastic polymer-film-coated cap. After the capture on to the cap, the samples were used for RNA analysis. The total RNA from captured cells was extracted in the same manner as the whole tissue and subjected to RT-PCR as previously described.
RESULTS
Immunohistochemistry
In normal skin, the CRH, CRH-R, and .-MSH immunoreactivities were observed in the same cells in the upper portion of the Malpighian layer and in melanocytes of the epidermis. The signals for CRH in the normal epidermis were weak, and the TSA method could demonstrate the immunoreactivity of CRH (Fig. 1A) (11) . Strong immunogenicities of CRH, CRH-R, and .-MSH were found in the sebaceous gland and outer root sheath of hair follicles (Figs. 1B and 2A , B, and C). We observed in the melanocytic nevus intense staining of CRH DQG.-MSH (Figs. 2D  and E) . The strong immunoreactivities of CRH-R and POMC peptides (ACTH) were localized not only in the tumor cells of seborrheic keratosis, but also in the peripheral epidermis (Fig. 2F  and G) .
CRH, CRH-R, and POMC mRNA expression detected by solution RT-PCR
The RT-PCR assay showed that all samples expressed CRH, CRH-R, and POMC mRNAs, not only in the pathologic skin (psoriastic, parapsoriastic, seborrheic keratosis, or nevus lesions) (data not shown), but also in normal skin (Fig. 4, left panel) . The sizes of PCR products are the same as those predicted from primer sequences and in agreement with previous reports (4).
Laser-capture microdissection with RT-PCR
Combining LCM with RT-PCR assay, we detected coexpression of CRH, CRH-R, and POMC mRNAs in captured sebaceous cells (Fig. 3 and Fig. 4 , right panel; the band of CRH mRNA was not shown). The sizes of PCR products were the same as those determined by solution RT-PCR by using the whole tissue from the same lesion.
mRNA expression detected by in situ RT-PCR
The in situ RT-PCR assay showed the coexpression of CRH and POMC mRNAs in epidermal keratinocytes and melanocytes (Fig. 5A, B, respectively) , as well as in sebaceous and sweat gland cells (Fig. 5C2) . Expressions of CRH mRNA in psoriastic epidermis (Fig. 5C1 ) and POMC mRNA in psoriastic and other inflammatory lesion (parapsoriastic lesions) (Fig. 5D ) were stronger and more extensive than in the normal epidermis. Dermal infiltrating cells also expressed CRH and POMC mRNAs.
DISCUSSION
Skin produces CRH and POMC peptides locally. The RT-PCR assay has demonstrated the presence of CRH, CRH-R, and POMC mRNAs in skin biopsy specimens and in cultured keratinocytes and melanocytes (4, 12, 13) . The immunoreactivity of POMC peptides has been localized in the upper layer of the epidermis and pilosebaceous units (14, 15) . In situ hybridization has shown that the production sites of POMC are in epidermal keratinocytes and melanocytes (16) . For CRH, Slominski et al. showed the localization of CRH peptides in the human scalp skin by indirect immunofluorescence methods (7), and Roloff et al. demonstrated the hair-cycle-dependent expressions of CRH and CRH-R in the murine skin (17) . In this study, by using the TSA method, we demonstrated immunoreactivity of CRH in the nonscalp human epidermis.
To determine the production sites of CRH and POMC peptides in the skin, we used the in situ RT-PCR assay, which revealed the expression of CRH and POMC mRNAs in epidermal keratinocytes and melanocytes, and pilosebaceous gland. Furthermore, LCM combined with the RT-PCR assay confirmed the localization of CRH, CRH-R, and POMC mRNA expressions in exactly the same sites where these peptides were detected by immunohistochemistry. The results indicate that epidermal and pilosebaceous cells are the source of cutaneous CRH and POMC peptides.
The regulatory mechanisms of CRH and POMC production are of particular interest. A comparison between pathologic lesions and normal skin on the expressions of CRH and POMC mRNAs suggested the possibility that inflammatory cytokines might regulate these expressions. In this study, strong immunoreactivities of CRH and POMC peptides were observed in the epidermis and dermal infiltrating cells of inflammatory lesions, and expressions of these mRNAs were stronger in inflamed epidermis than in normal skin. In the hypothalamus, release of CRH is stimulated by immune cell products, predominantly tumor necrosis factor . 71)-. DQG interleukin (IL)1 and IL-6 (18, 19) . IL-1 increases production of POMC mRNAs, ACTH and MSH peptides in cultured epidermal keratinocytes, and melanocytes (20) (21) (22) (23) . It is therefore speculated that the strong expressions of CRH and POMC mRNAs in the psoriastic epidermis and dermal-infiltrating monocytes might be stimulated by inflammatory cytokines. Slominski et al. suggested similarly that the immune system could play a dominant regulatory role in POMC peptide production in the skin (24) . Furthermore, CRH and POMC peptides might interact with immune system. Because CRH and POMC peptides have a direct immunomodulatory role. CRH could act on immune cells to elicit proinflammatory responses; CRH stimulates secretion of IL-1 (25) and IL-6 from mononuclear cells (26) and promotes lymphocyte proliferation (27) (28) . On WKH RWKHU KDQG .-MSH has been known to have inhibitory effects on peripheral host cells in which it reduces the release of proinflammatory mediators. Our results support the hypothesis proposed by Slominski et al. (29) , that a stress response system may exist in the skin mediated by the neuroendocrine system and modulated by the immune system, with the CRH-POMC loop playing an essential role.
Melanocytic nevus cells also showed intense immunoreactivity of CRH, CRH-R, and POMC peptides. In the CNS, hypothalamic CRH stimulates POMC mRNA expression and .-MSH production in the pituitary gland via CRH-R. Coexpression of CRH, CRH-R, and POMC peptides in nevus cells suggests the presence of a regulatory loop between CRH and POMC activated in an autocrine and paracrine manner, as in the CNS. Makrigiannakis et al. proposed the same speculation based on their study on the human uterus (30) .
The peripheral epidermis of seborrheic keratosis showed strong immunoreactivities of CRH, CRH-R, and POMC peptides. Based on their study of malignant melanoma, Liu and Johansson reported that tissues peripheral to the melanoma, such as the sweat gland, sebaceous gland, and hair follicles, strongly expressed MSHs compared with the control tissues (21) . They proposed a possibility that melanoma cells might autonomously produce MSHs secreted into blood circulation and among the cells to promote self-proliferation, extending to the perilesional tissue. They speculated another possibility that the perilesional tissues could synthesize MSH peptides due to the effect of proliferation of melanoma cells (21) . In this study, tumor cells expressed CRH and POMC peptides strongly; therefore, POMC peptides in the perilesional tissue might be produced locally underlying a cross-talk between the tumor cells and perilesional cells. Moreover, external stressors, predominantly ultraviolet light, were found to stimulate expressions of CRH and POMC as a response to stress. The peripheral tissue, thereby, may synthesize the POMC peptides as a response to local stress and tumor progression. As previously supposed, POMC peptides produced in the peripheral lesions may have a role in generating an environment permissive for tumor development and progression. .-MSH and ACTH act as potent immunosuppressors (31) (32) (33) , and .-MSH can regulate the cytoprotective protein equipment in keratinocytes (34) . Indeed, MSH has been reported to enhance the proliferation and metastatic ability of malignant melanoma (35) . Slominski et al. also observed heterogeneous distribution and expression of POMC peptides, as well as their mRNAs in basal cell carcinoma (BCC) and in the peripheral area (36) . They also showed the expression of the MC-1 gene encoding the active receptor for MSH and ACTH in the same lesional and perilesional skin (36) . From this observation, they suggested that POMC peptides facilitate BCC development and/or progression (24) .
In summary, we have demonstrated the presence of CRH, CRH-R, and POMC peptides in the human skin and localizations of expressions of their mRNAs. The peptides and mRNAs were expressed strongly in inflamed lesions and melanocytic nevus as well as in the periphery of lesions. These results imply the existence of autoregulatory loops of CRH and POMC expressions involving autocrine and paracrine mechanisms, as well as a cross-talk between the expressing cells and the cells of the immune system in the human skin. Our results further support a previous report that the cutaneous expression of the CRH/POMC function is organized similarly to the hypothalamic-pituitary-adrenal (HPA) axis to respond to stresses (24) . 
